Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
Published inCritical care medicine, vol. 29, no. 3, p. 503-510
Publication date2001
Abstract
Keywords
- Apache
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Canada/epidemiology
- Double-Blind Method
- Drug Monitoring
- Europe/epidemiology
- Female
- Humans
- Immunoglobulin G/immunology/pharmacology/ therapeutic use
- Immunoglobulin Heavy Chains
- Immunoglobulin gamma-Chains
- Interleukin-6/blood
- Male
- Middle Aged
- Multiple Organ Failure/microbiology
- Receptors, Tumor Necrosis Factor/immunology/ therapeutic use
- Recombinant Fusion Proteins/immunology/pharmacology/ therapeutic use
- Sepsis/blood/complications/ drug therapy/immunology/mortality
- Severity of Illness Index
- Shock, Septic/blood/complications/ drug therapy/immunology/mortality
- United States/epidemiology
Affiliation
Citation (ISO format)
ABRAHAM, E. et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. In: Critical care medicine, 2001, vol. 29, n° 3, p. 503–510. doi: 10.1097/00003246-200103000-00006
Main files (1)
Article
Identifiers
- PID : unige:7066
- DOI : 10.1097/00003246-200103000-00006
- PMID : 11373411
ISSN of the journal0090-3493